Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) were up 5% during trading on Wednesday . The company traded as high as $18.21 and last traded at $18.15, with a volume of 80,098 shares trading hands. The stock had previously closed at $17.28.

A number of analysts have commented on NTLA shares. Leerink Swann started coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price objective for the company. Credit Suisse Group AG started coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price objective for the company. Jefferies Group started coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a “hold” rating and a $33.00 price target for the company. Finally, Wedbush started coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 price target for the company.

The firm’s 50 day moving average is $23.79 and its 200-day moving average is $24.68. The stock’s market capitalization is $644.69 million.

In related news, Director Carl L. Gordon acquired 250,000 shares of Intellia Therapeutics stock in a transaction on Wednesday, May 11th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $4,500,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Institutes For Biomed Novartis acquired 277,777 shares of Intellia Therapeutics stock in a transaction on Wednesday, May 11th. The shares were bought at an average price of $18.00 per share, for a total transaction of $4,999,986.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.